医学
2型糖尿病
置信区间
二甲双胍
利西塞纳泰德
糖尿病
危险系数
临床终点
内科学
随机对照试验
内分泌学
基础胰岛素
作者
Ming Liu,Weijun Gu,Li Chen,Yanbing Li,Hongyu Kuang,Jianling Du,Agustina Alvarez,Felipe Lauand,Elisabeth Souhami,Jiewen Zhang,Weiya Xu,Qin Du,Yiming Mu,SoliD trial investigators
摘要
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
科研通智能强力驱动
Strongly Powered by AbleSci AI